CA3210098A1 - Microsphere formulations comprising lurasidone and methods for making and using the same - Google Patents
Microsphere formulations comprising lurasidone and methods for making and using the same Download PDFInfo
- Publication number
- CA3210098A1 CA3210098A1 CA3210098A CA3210098A CA3210098A1 CA 3210098 A1 CA3210098 A1 CA 3210098A1 CA 3210098 A CA3210098 A CA 3210098A CA 3210098 A CA3210098 A CA 3210098A CA 3210098 A1 CA3210098 A1 CA 3210098A1
- Authority
- CA
- Canada
- Prior art keywords
- polymer
- microsphere
- lurasidone
- microspheres
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163152943P | 2021-02-24 | 2021-02-24 | |
| US63/152,943 | 2021-02-24 | ||
| US202263267403P | 2022-02-01 | 2022-02-01 | |
| US63/267,403 | 2022-02-01 | ||
| PCT/US2022/070807 WO2022183196A1 (en) | 2021-02-24 | 2022-02-24 | Microsphere formulations comprising lurasidone and methods for making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3210098A1 true CA3210098A1 (en) | 2022-09-01 |
Family
ID=82900191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3210098A Pending CA3210098A1 (en) | 2021-02-24 | 2022-02-24 | Microsphere formulations comprising lurasidone and methods for making and using the same |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11992559B2 (enExample) |
| EP (1) | EP4297753A4 (enExample) |
| JP (1) | JP2024507528A (enExample) |
| KR (1) | KR20230157365A (enExample) |
| AU (1) | AU2022226584A1 (enExample) |
| CA (1) | CA3210098A1 (enExample) |
| IL (1) | IL304650A (enExample) |
| MX (1) | MX2023009754A (enExample) |
| WO (1) | WO2022183196A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119424341A (zh) * | 2023-08-02 | 2025-02-14 | 珠海市华海康医药科技有限责任公司 | 一种注射用药物缓释微球及其制备方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| US5288502A (en) | 1991-10-16 | 1994-02-22 | The University Of Texas System | Preparation and uses of multi-phase microspheres |
| EP0724432B1 (en) | 1993-10-22 | 2002-09-18 | Genentech, Inc. | Methods and compositions for microencapsulation of antigens for use as vaccines |
| ATE288270T1 (de) | 1993-11-19 | 2005-02-15 | Janssen Pharmaceutica Nv | Mikroverkapselte 1,2-benzazole |
| PT1615959E (pt) | 2003-04-10 | 2013-08-29 | Evonik Corp | Um método para a produção de micropartículas à base de emulsão |
| WO2005009356A2 (en) | 2003-07-15 | 2005-02-03 | Pr Pharmaceuticals, Inc. | Method for the preparation of controlled release formulations |
| JP2008518881A (ja) | 2003-07-18 | 2008-06-05 | オークウッド ラボラトリーズ，エル．エル．シー． | 高分子組成物中の高分子の分子量低下、不純物形成およびゲル化の防止 |
| AU2004259209A1 (en) | 2003-07-23 | 2005-02-03 | Pr Pharmaceuticals, Inc. | Controlled release compositions |
| WO2006134864A1 (ja) | 2005-06-13 | 2006-12-21 | Dainippon Sumitomo Pharma Co., Ltd. | 可溶化型製剤 |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| US8202524B2 (en) | 2006-08-31 | 2012-06-19 | Sk Chemicals Co., Ltd. | Method for producing microspheres loaded with drugs and microspheres loaded with drugs produced thereby |
| CA2709712C (en) | 2007-12-20 | 2016-05-10 | Surmodics Pharmaceuticals, Inc. | Process for preparing microparticles having a low residual solvent volume |
| KR20120035183A (ko) | 2009-06-10 | 2012-04-13 | 선오비온 파마슈티컬스 인코포레이티드 | 히스타민 ｈ3 역 작용제 및 길항제, 및 이의 사용 방법 |
| AU2010339689B2 (en) | 2010-01-07 | 2015-02-19 | Alkermes Pharma Ireland Limited | Quaternary ammonium salt prodrugs |
| US10335366B2 (en) * | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| CN107595771A (zh) | 2010-10-18 | 2018-01-19 | 大日本住友制药株式会社 | 注射用缓释制剂 |
| SG190009A1 (en) | 2010-11-24 | 2013-06-28 | Univ Nanyang Tech | Method for encapsulating particles |
| AU2011348085B2 (en) | 2010-12-23 | 2016-12-08 | Alkermes Pharma Ireland Limited | Multi- API loading prodrugs |
| WO2013142205A1 (en) | 2012-03-19 | 2013-09-26 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
| WO2014076712A2 (en) | 2012-11-14 | 2014-05-22 | Hetero Research Foundation | Lurasidone hydrochloride solid dispersion |
| US9393211B2 (en) | 2013-03-15 | 2016-07-19 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
| US9956177B2 (en) | 2013-03-15 | 2018-05-01 | Oakwood Laboratories LLC | Sustained release microspheres and method of producing same |
| US9636308B2 (en) | 2013-03-15 | 2017-05-02 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
| RU2658004C2 (ru) * | 2013-06-20 | 2018-06-19 | Фарматен С.А. | Получение полилактидно-полигликолидных микрочастиц, характеризующихся сигмоидальным профилем высвобождения |
| CA3148303C (en) * | 2013-12-03 | 2024-02-27 | Intra-Cellular Therapies, Inc. | Heterocycle fused gamma-carboline compounds for use in treatment of bipolar disorders |
| US20150157628A1 (en) | 2013-12-11 | 2015-06-11 | Saravanan Kannusamy | Pharmaceutical compositions of Lurasidone and Process for preparation thereof |
| EP3242653A1 (en) | 2015-01-05 | 2017-11-15 | Boston Scientific Scimed Inc. | Biodegradable drug eluting microsphere for the treatment of solid tumors |
| WO2017059106A1 (en) | 2015-09-30 | 2017-04-06 | Indivior Uk Limited | Psychiatric treatment for patients with gene polymorphisms |
| WO2017119928A1 (en) | 2016-01-08 | 2017-07-13 | Abon Pharmaceuticals, Llc | Long acting injectable formulations |
| WO2018015915A1 (en) * | 2016-07-22 | 2018-01-25 | Cadila Healthcare Limited | A parenteral controlled release composition of an atypical antipsychotic agent |
-
2022
- 2022-02-24 JP JP2023550249A patent/JP2024507528A/ja active Pending
- 2022-02-24 MX MX2023009754A patent/MX2023009754A/es unknown
- 2022-02-24 US US17/679,385 patent/US11992559B2/en active Active
- 2022-02-24 KR KR1020237032096A patent/KR20230157365A/ko active Pending
- 2022-02-24 WO PCT/US2022/070807 patent/WO2022183196A1/en not_active Ceased
- 2022-02-24 AU AU2022226584A patent/AU2022226584A1/en active Pending
- 2022-02-24 CA CA3210098A patent/CA3210098A1/en active Pending
- 2022-02-24 EP EP22760617.5A patent/EP4297753A4/en active Pending
-
2023
- 2023-07-23 IL IL304650A patent/IL304650A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL304650A (en) | 2023-09-01 |
| JP2024507528A (ja) | 2024-02-20 |
| US20220265562A1 (en) | 2022-08-25 |
| AU2022226584A1 (en) | 2023-08-17 |
| EP4297753A1 (en) | 2024-01-03 |
| MX2023009754A (es) | 2023-08-30 |
| EP4297753A4 (en) | 2025-01-01 |
| US11992559B2 (en) | 2024-05-28 |
| WO2022183196A1 (en) | 2022-09-01 |
| KR20230157365A (ko) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018223894A1 (zh) | 一种长效缓释药物制剂及其制备方法 | |
| CA2765695C (en) | Method of making sustained release microparticles | |
| EP2968577A1 (en) | High drug load buprenorphine microspheres and method of producing the same | |
| EP4308106A1 (en) | Microsphere formulations comprising naltrexone and methods for making and using the same | |
| US11992559B2 (en) | Microsphere formulations comprising lurasidone and methods for making and using the same | |
| TWI906350B (zh) | 包括氯胺酮的微球調配物、其製造方法及使用於方法中之組合物 | |
| US20240307381A1 (en) | Microsphere formulations comprising lurasidone and methods for making and using the same | |
| US20240216280A1 (en) | Microsphere formulations comprising nalmefene andmethods for making and using the same | |
| US20240000772A1 (en) | Microsphere formulations comprising naltrexone and methods for making and using the same | |
| CN116916920A (zh) | 包含鲁拉西酮的微球制剂及其制备和使用方法 | |
| WO2025117624A1 (en) | Microsphere formulations comprising brexpiprazole and methods for making and using the same | |
| WO2024163997A1 (en) | Microsphere formulations comprising naltrexone and methods for making and using the same | |
| US20250032451A1 (en) | Microsphere formulations comprising asenapine and methods for making and using the same | |
| CA3210001A1 (en) | Microsphere formulations comprising btk inhibitors and methods for making and using the same | |
| US20230404922A1 (en) | Microsphere formulations comprising btk inhibitors and methods for making and using the same | |
| EP4611729A1 (en) | Mixed release profile polymer microsphere formulations comprising octreotide and methods for making and using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250216 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250216 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250216 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250319 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250319 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250319 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250331 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250407 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250407 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250407 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250516 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260206 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260212 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260212 |